The Irish Cancer Society highlights failures in Ireland’s two-tier health system, which disadvantages public cancer patients. Experts, including Dr. Michael McCarthy, reveal that 30-40% of new EMA-approved cancer drugs are unavailable to public patients, who face an average two-year wait for access. Urging the next government to prioritize funding for the National Cancer Strategy, McCarthy stresses the need for equitable access to groundbreaking treatments. The HSE’s role in drug approval processes and the impact of delays from drug manufacturers are also criticized.